although
year
pass
sinc
edward
jenner
conduct
first
human
clinic
trial
smallpox
vaccin
vaccin
rout
remain
unchang
subcutan
intramuscular
remain
two
main
rout
vaccin
worldwid
administr
rout
one
factor
render
vaccin
unafford
unavail
thirdworld
countri
hurdl
encount
includ
refriger
transport
need
health
profession
administ
vaccin
led
higher
cost
shortcom
tradit
vaccin
becom
deterr
effort
improv
world
health
standard
order
amelior
problem
altern
vaccin
rout
oral
nasal
buccal
offer
new
hope
among
altern
rout
oral
rout
prefer
result
advantag
rout
concept
oral
vaccin
explor
numer
research
oral
vaccin
begun
emerg
market
includ
polio
oral
vaccin
oral
vaccin
travel
diarrhea
cholera
advantag
oral
vaccin
includ
improv
patient
complianc
eas
administr
lower
cost
product
transport
also
serv
altern
needl
phobic
includ
young
children
elderli
importantli
oral
vaccin
capabl
induc
mucos
system
immun
recent
studi
suggest
order
produc
effect
vaccin
system
mucos
immun
induc
nevertheless
oral
deliveri
protein
vaccin
face
major
physiolog
barrier
acid
environ
stomach
enzymat
environ
throughout
intestin
well
formul
challeng
stabil
target
issu
despit
challeng
signific
level
success
wit
veterinari
field
oral
deliveri
mycobacterium
pneumonia
vaccin
biolog
vaccin
gener
consist
larg
molecul
consist
peptid
protein
conjug
unlik
deliveri
small
molecul
product
special
consider
make
challeng
deliv
site
action
receptor
import
consider
stabil
activ
protein
peptid
formul
maintain
basic
structur
tertiari
structur
obtain
optim
effect
ideal
deliveri
system
would
protect
protein
peptid
antigen
physiolog
condit
encount
administr
allow
retain
structur
primari
tertiari
reach
site
action
attempt
deliv
biolog
vaccin
oral
numer
strategi
carri
scientist
around
world
use
variou
vehicl
microparticl
liposom
viruslik
particl
vlp
lectin
immun
stimul
complex
iscom
chapter
discuss
variou
nonparenter
rout
employ
deliveri
product
nonparenter
rout
offer
eas
administr
biolog
formul
nonprofession
set
promis
greater
patient
complianc
formul
biolog
includ
protein
difficult
without
understand
structur
physicochem
properti
protein
peptid
form
bind
variou
amino
acid
natur
occur
amino
acid
differ
side
chain
protein
contain
amino
acid
wherea
peptid
contain
fewer
amino
acid
four
level
protein
structur
primari
secondari
tertiari
quaternari
primari
structur
includ
sequenc
coval
bond
amino
acid
dictat
sequenc
deoxyribonucl
acid
dna
secondari
structur
consist
ahelix
bsheet
random
coil
bbend
small
loop
polypeptid
chain
tertiari
structur
protein
includ
overal
pack
space
variou
element
secondari
structur
quaternari
structur
repres
specif
associ
separ
protein
chain
form
welldefin
structur
primari
structur
protein
dictat
fold
process
gener
overal
shape
spheric
polar
group
surfac
hydrophob
group
buri
interior
fold
structur
protein
stabil
noncoval
coval
forc
forc
includ
disulfid
bridg
cystein
residu
hydrogen
bond
salt
bridg
ionic
group
hydrophob
interact
side
chain
amino
acid
residu
evid
discuss
protein
intric
structur
make
formul
protein
challeng
task
order
success
formul
protein
stabil
bioactiv
must
maintain
shelf
life
year
reach
intend
target
subtl
chang
secondari
tertiari
quaternari
structur
lead
physic
instabl
denatur
aggreg
precipit
adsorpt
addit
hydrolysi
deamid
oxid
disulfid
exchang
belimin
racem
lead
chemic
instabl
protein
henc
degrad
pathway
need
avoid
formul
process
strategi
minim
probabl
induct
place
strategi
includ
reduc
thermal
stress
use
lowest
temperatur
possibl
spray
dri
store
protein
ph
harsh
chemic
strong
acid
base
organ
solvent
disrupt
higher
order
structur
protein
use
among
mani
vehicl
success
deliveri
biolog
microparticl
microparticl
beadlik
particl
diamet
greater
mm
mostli
spheric
shape
microparticul
deliveri
system
use
wide
rang
drug
includ
neoplast
agent
vaccin
inactiv
bacteria
protein
peptid
matrix
microparticl
categor
two
class
monolith
reservoir
monolith
matrix
activ
agent
dispers
homogen
within
polym
matrix
wherea
reservoir
matrix
drug
surround
polym
matrix
mononuclear
polynuclear
state
core
monolith
matrix
advantag
avoid
risk
dose
dump
due
ruptur
membran
reservoir
matrix
drug
releas
monolith
matrix
may
depend
solubl
drug
matrix
well
poros
tortuos
polym
network
microparticul
deliveri
system
offer
abil
flexibl
allow
formul
sustain
controlledreleas
system
organ
tissu
target
capabl
microparticl
shown
select
target
drug
organ
diseas
site
microparticl
also
possess
abil
sustain
control
releas
variou
drug
addit
microparticl
act
immunolog
adjuv
light
fact
particul
natur
furthermor
stealth
microparticl
produc
addit
polyethylen
glycol
peg
thu
enabl
chemic
attach
peg
chain
broad
rang
substanc
pegyl
process
increas
halflif
circul
improv
drug
solubl
stabil
reduc
immunogen
convent
chemotherapi
cancer
treatment
wide
use
clinic
associ
signific
system
toxic
bigger
problem
reoccurr
tumor
immunotherapi
recent
develop
boost
immun
system
detect
cancer
prevent
reoccurr
thu
improv
patient
qualiti
life
chapter
talk
immunolog
strategi
cancer
vaccin
research
could
potenti
therapi
futur
first
discuss
variou
nonparenter
rout
administr
therapi
associ
immunolog
structur
rout
mechanist
pathway
act
later
chapter
provid
specif
exampl
oral
rout
administr
attract
mode
immun
eas
administr
low
manufactur
cost
high
patient
complianc
intestin
peyer
patch
predomin
site
oral
administr
case
particl
uptak
depend
variou
factor
size
charg
hydrophob
oral
deliveri
report
particl
size
less
mm
posit
charg
hydrophob
natur
preferenti
enter
peyer
patch
small
intestin
oral
deliv
vaccin
especi
particul
antigen
recogn
sampl
microfold
cell
peyer
patch
follow
transport
particl
underli
follicl
profession
antigenpres
cell
apc
dendrit
cell
macrophag
apc
phagocytos
particl
process
present
major
histocompat
complex
mhc
class
cross
prime
mhc
class
ii
molecul
result
b
cell
trigger
shown
figur
major
hurdl
oral
deliveri
protect
activ
biolog
entiti
acid
enzymat
degrad
gastrointestin
tract
anoth
obstacl
consid
design
oral
vaccin
biolog
probabl
oral
toler
low
particl
uptak
gastric
degrad
product
antigen
caus
oral
toler
one
way
avoid
issu
formul
microparticl
enter
coat
polym
variou
studi
report
describ
use
enter
coat
polym
eudragit
l
l
cellulos
acet
phthalat
hydroxylpropyl
methylcellulos
phthalateacet
succin
polym
particul
deliveri
vehicl
polym
solubl
ph
thu
render
protect
antigen
activ
gastric
media
oral
deliveri
vaccin
antigen
biolog
use
polymer
microparticl
offer
remark
advantag
other
induct
mucos
well
system
immun
respons
protect
antigen
gastric
degrad
prolong
present
antigen
immun
system
obviat
need
vaccin
adjuv
microparticl
act
selfadjuv
strateg
design
particul
deliveri
system
incorpor
enter
polym
protect
biolog
entiti
harsh
gastric
condit
target
ligand
enhanc
uptak
cell
peyer
patch
small
intestin
cell
microfold
cell
act
sampl
port
foreign
entiti
encount
small
intestin
cell
hous
variou
dendrit
cell
immun
cell
oral
vaccin
particl
sampl
cell
process
dendrit
cell
antigenpres
cell
present
mhc
class
class
ii
molecul
antigen
recogn
immun
cell
vicin
lead
cascad
immun
respons
shown
figur
immun
respons
also
includ
humor
respons
plasma
b
cell
lead
product
antibodi
class
switch
role
b
cell
debat
past
recent
studi
mahmoud
et
al
show
humor
immun
import
addit
cellmedi
immun
prognosi
cancer
thu
rout
trigger
humor
cellmedi
immun
respons
variou
cancer
vaccin
biolog
use
microparticl
cancer
therapi
deliveri
biolog
via
oral
rout
discuss
later
chapter
oral
rout
drug
deliveri
prefer
rout
patient
clinician
howev
drawback
associ
hepat
firstpass
metabol
enzymat
degrad
gastrointestin
tract
reason
mucos
site
consid
altern
oral
rout
altern
mucos
rout
drug
deliveri
eg
nasal
rectal
vagin
ocular
buccal
sublingu
offer
advantag
peror
rout
respect
bypass
firstpass
metabol
enzymat
degrad
gastrointestin
tract
nasal
rout
drug
administr
studi
reach
commerci
statu
drug
lutein
hormonereleas
hormon
lhrh
calcitonin
howev
disadvantag
irrit
nasal
mucosa
damag
ciliari
action
nasal
caviti
due
chronic
use
nasal
dosag
form
limit
use
drug
deliveri
system
larg
intraand
intersubject
variabl
also
affect
drug
absorpt
site
similarli
rectal
vagin
ocular
site
offer
advantag
oral
rout
time
poor
patient
complianc
oral
caviti
hand
much
accept
patient
permeabl
rich
blood
suppli
robust
recov
quickli
stress
damag
buccal
sublingu
deliveri
help
avoid
firstpass
metabol
presystem
elimin
gastrointestin
tract
oral
mucosa
consist
outermost
layer
stratifi
squamou
epithelium
lie
basement
membran
lamina
propria
figur
similar
stratifi
squamou
epithelia
found
elsewher
bodi
basal
cell
layer
number
differenti
intermedi
layer
epitheli
layer
increas
size
becom
flatter
travel
basal
superfici
layer
turnov
time
buccal
epithelium
estim
five
six
day
probabl
repres
oral
mucosa
whole
oral
mucos
thick
vari
depend
site
buccal
mucosa
measur
mm
wherea
mucos
thick
hard
soft
palat
floor
mouth
ventral
tongu
gingiva
measur
mm
composit
epithelium
also
vari
depend
site
oral
caviti
mucosa
area
subject
mechan
stress
gingiva
hard
palat
keratin
similar
epidermi
mucosa
soft
palat
sublingu
buccal
region
howev
keratin
keratin
epithelia
rel
imperm
water
contrast
nonkeratin
epithelia
floor
mouth
buccal
epithelia
contain
acylceramid
small
amount
ceramid
also
contain
small
amount
neutral
polar
lipid
mainli
cholesterol
sulfat
glucosyl
ceramid
epithelia
found
consider
permeabl
water
keratin
epithelia
import
vaccin
bacteri
viral
pathogen
elicit
mucos
immun
pathogen
primarili
attack
mucos
surfac
bodi
also
administr
vaccin
mucos
sitesor
nasal
vagin
rectalha
proven
effect
patient
compliant
howev
still
lack
vaccin
deliv
rout
probabl
due
challeng
associ
develop
effect
stabl
vaccin
deliv
rout
one
mucos
rout
drug
deliveri
larg
neglect
vaccin
deliveri
buccal
rout
mucos
surfac
oral
caviti
ideal
site
vaccin
easi
access
good
antigen
present
buccal
caviti
rich
dendrit
cell
similar
langerhan
cell
type
antigenpres
cell
also
high
densiti
lymphocyt
mucosalassoci
lymphoid
tissu
tonsil
salivari
gland
waldey
ring
pharyng
lymphoid
tissu
present
buccal
mucosa
henc
buccal
immun
help
elicit
mucos
system
immun
etchart
et
al
report
immun
dna
inject
buccal
mucosa
mice
induc
measl
viru
hemagglutininspecif
cytotox
lymphocyt
respons
spleen
also
seen
lundholm
et
al
pdna
administ
oral
cheek
mice
use
jet
inject
induc
product
immunoglobulin
iga
signifi
mucos
immun
respons
wang
et
al
report
mucos
deliveri
melanoma
vaccin
hamster
model
help
treat
oral
melanoma
distant
skin
lesion
studi
demonstr
buccal
immun
possibl
effect
time
establish
efficaci
buccal
vaccin
next
step
develop
robust
effect
deliveri
system
liquid
formul
contain
vaccin
adjuv
studi
anim
far
henc
need
develop
deliveri
system
prolong
resid
buccal
mucosa
coupl
retent
efficaci
stabil
vaccin
antigen
adjuv
pulmonari
deliveri
around
long
time
origin
earli
civil
howev
becom
increasingli
popular
increasingli
explor
altern
mean
system
deliveri
drug
includ
larg
number
protein
peptid
sinc
latter
part
centuri
pulmonari
deliveri
use
local
deliveri
drug
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
recent
also
consid
viabl
altern
system
deliveri
small
larg
molecul
biolog
certainli
replac
convent
small
molecul
drug
therapi
futur
potenc
specif
give
edg
make
popular
pharmaceut
biotechnolog
industri
howev
challeng
associ
deliveri
inher
properti
high
molecular
weight
hydrophil
instabl
predominantli
administ
parenter
rout
ensur
direct
entri
system
circul
order
improv
patient
complianc
mani
noninvas
rout
deliveri
explor
pulmonari
deliveri
one
pulmonari
deliveri
emerg
promis
altern
uniqu
anatom
featur
lung
lung
provid
larg
absorpt
surfac
area
extrem
thin
mm
absorpt
mucos
membran
excel
vascular
challeng
incorpor
drug
formul
deliv
depth
lung
permit
permeat
drug
blood
circul
respiratori
system
equip
seri
filter
design
protect
lung
undesir
environment
materi
keep
lung
clean
factor
must
taken
consider
particular
therapi
suffici
effect
low
effici
larg
variabl
major
factor
prevent
rout
administr
gain
complet
accept
factor
affect
deposit
drug
alveolar
region
lung
uptak
alveolar
macrophag
proteolyt
degrad
number
formul
paramet
uniqu
pulmonari
deliveri
aerodynam
particl
behavior
particl
size
densiti
hygroscop
shape
surfac
charg
breath
pattern
patient
flow
rate
ventil
volum
airway
anatomi
morphometri
patient
irrespect
type
drug
deliv
small
molecul
larg
molecul
factor
consid
prepar
formul
pulmonari
deliveri
meter
dose
inhal
mdi
dri
powder
inhal
dpi
tradit
use
deliveri
measur
dose
lung
commonli
use
deliv
drug
lung
treatment
diseas
asthma
copd
anoth
commerci
avail
system
aerx
pulmonari
deliveri
system
aradigm
use
bolu
aerosol
particl
deliv
certain
time
inspir
bolu
produc
piston
empti
small
liquid
reservoir
inhal
air
devic
includ
akita
inhal
system
activaero
system
profil
therapeut
also
use
bolu
inhal
techniqu
deposit
particl
lung
bolu
deliveri
techniqu
help
increas
particl
deposit
lung
nectar
therapeut
along
pfizer
came
exubera
inhal
deliveri
insulin
treatment
diabet
form
insulin
expect
replac
form
inject
insulin
product
last
market
littl
year
introduc
septemb
soon
recal
cost
ineffect
provid
efficaci
inject
insulin
sinc
number
compani
eg
mannkind
corpor
aerogen
danc
biopharm
attempt
develop
form
inhal
insulin
less
expens
produc
exubera
besid
insulin
protein
peptid
whose
deliveri
attempt
pulmonari
rout
hormon
eg
insulin
calcitonin
growth
hormon
somatostatin
thyroidstimul
hormon
folliclestimul
hormon
growth
factor
eg
granulocytemonocyt
colonystimul
factor
granulocyt
colonystimul
factor
variou
interleukin
heparin
mani
problem
associ
stabil
absorpt
macromolecul
resolv
product
current
show
promis
clinic
studi
prove
spite
larg
number
challeng
pulmonari
deliveri
biolog
face
start
progress
made
leap
bound
thu
prove
potenti
concept
immun
evolv
knowledg
work
bodi
defens
system
vaccin
tradit
made
use
live
attenu
fragment
pathogen
transderm
rout
explor
deliv
vaccin
noninvas
skin
thu
offer
number
benefit
needlefre
deliveri
transderm
vaccin
deliveri
tvd
achiev
directli
appli
vaccin
antigen
topic
antigenpres
cell
epidermi
dermi
better
known
langerhan
cell
interact
antigen
initi
adapt
immun
respons
migrat
skin
drain
lymph
node
activ
cell
b
cell
technolog
howev
limit
due
fact
vaccin
largemolecularweight
antigen
mani
instanc
find
difficult
cross
outer
barrier
skin
stratum
corneum
moreov
topic
appli
macromolecul
may
get
lodg
hair
follicl
sweat
duct
prevent
vaccin
reach
effect
concentr
skin
numer
method
success
use
bypass
stratum
corneum
chemic
enhanc
electropor
ultrasound
iontophoresi
use
microneedl
method
potenti
increas
skin
permeabl
larg
number
therapeut
substanc
includ
macromolecul
insulin
vaccin
method
increas
transderm
transport
use
chemic
enhanc
increas
drug
solubl
increas
diffus
coeffici
chemic
enhanc
ultrasound
electropor
extern
drive
forc
ultrasound
iontophoresi
electropor
stratum
corneum
outermost
layer
skin
thick
mm
protect
microb
fluid
foreign
materi
also
signific
barrier
transderm
deliveri
mani
compound
includ
vaccin
much
research
carri
field
transderm
vaccin
deliveri
recent
year
bhowmik
et
al
formul
microparticul
whole
cell
lysat
vaccin
compos
melanoma
cell
line
antigen
biodegrad
matrix
bovin
serum
albumin
bsa
sustainedreleas
polym
particl
rang
size
mm
formul
deliv
transderm
creat
microchannel
skin
fourto
sixweekold
mice
use
dermarol
devic
use
microneedl
technolog
vivo
studi
show
vaccin
produc
increas
immun
respons
signific
increas
igg
antibodi
titer
observ
may
result
uptak
present
antigen
langerhan
cell
skin
also
vaccin
mice
show
palpabl
tumor
even
observ
day
tumor
induct
thu
transderm
microparticl
deliveri
vaccin
open
new
avenu
vaccin
administr
use
rather
noninvas
methodolog
requir
modif
test
clinic
set
ongo
research
explor
drug
deliveri
system
organ
nanoparticl
hydrogel
polymerbas
particl
solidlipid
nanoparticl
liposom
well
lipidbas
vesicl
transcutan
vaccin
deliveri
nanoparticl
shown
promis
carrier
transcutan
vaccin
advantag
small
size
allow
penetr
hair
follicl
caus
vaccin
antigen
target
antigenpres
cell
augment
immun
respons
addit
interact
skin
lipid
result
gener
transient
revers
open
stratum
corneum
polym
polylact
acid
polylacticcoglycol
acid
chitosan
shown
promis
transderm
immun
elicit
strong
immun
respons
liposom
excit
carrier
system
deliveri
vaccin
via
transderm
rout
lipidbas
vesicl
liposom
especi
elast
liposom
may
chang
bioactiv
permeat
kinet
due
impair
barrier
function
stratum
corneum
help
skin
penetr
liposom
gener
compos
phosphatidylcholin
surfact
contain
lipid
bilay
envelop
aqueou
compart
larg
capac
load
drug
vaccin
mishra
et
al
demonstr
enhanc
immun
antigen
use
elast
liposom
load
hepat
b
surfac
antigen
hbsag
research
area
develop
novel
nanos
formul
may
help
regard
stabil
antigen
protect
disrupt
lipid
stratum
corneum
properti
primari
import
deliveri
vaccin
skin
howev
develop
novel
nanoscal
system
limit
low
effici
elicit
robust
immun
respons
clinic
trial
transcutan
immun
usual
reli
microneedl
needlefre
skin
patch
research
clinic
trial
concentr
transderm
vaccin
infecti
diseas
influenza
cancer
immun
take
back
seat
develop
futur
vaccin
deliveri
strategi
requir
investig
transderm
rout
research
work
publish
thu
far
shown
great
promis
chemotherapi
common
treatment
cancer
use
anticanc
drug
kill
cancer
tissu
chemotherapi
singl
drug
combin
drug
use
particular
cancer
along
treatment
surgeri
radiat
chemotherapi
may
use
achiev
total
remiss
prevent
reoccurr
cancer
slow
metastasi
chemotherapeut
drug
gener
given
oral
inject
could
drug
exert
cytotox
effect
cancer
cell
healthi
cell
around
cancer
could
also
reach
part
bodi
caus
mild
devast
side
effect
side
effect
chemotherapeut
drug
rang
mild
symptom
fatigu
loss
appetit
sever
effect
vomit
neutropenia
lead
poor
qualiti
life
moreov
drug
administ
intraven
rout
could
caus
seriou
effect
extravas
although
much
progress
made
allevi
side
effect
caus
chemotherapi
need
improv
therapi
less
damag
patient
cancer
immunotherapi
design
modifi
host
immun
system
util
compon
immun
system
cancer
treatment
immunotherapi
may
prefer
tradit
chemotherapi
treatment
offer
less
sever
side
effect
sometim
may
target
therapi
immunolog
product
receiv
regulatori
approv
either
singl
anticanc
agent
combin
chemotherapi
product
includ
cytokin
interferona
monoclon
antibodi
trastuzumab
bevacizumab
ipilimumab
other
anticanc
cellbas
therapi
sipuleucelt
cellmedi
immun
respons
enhanc
tumor
cell
offer
variou
advantag
target
therapi
particularli
gener
longtermmemori
lymphocyt
popul
patrol
bodi
attack
metastas
becom
visibl
tradit
imag
modal
signific
interest
develop
therapeut
cancer
vaccin
last
decad
led
improv
overal
surviv
cancer
patient
sever
clinic
trial
result
two
activ
immunotherapi
agent
sipuleucelt
ipilimumab
approv
us
food
drug
administr
fda
treatment
prostat
cancer
melanoma
respect
gvax
cellular
vaccin
cell
genesysi
inc
anoth
activ
immunotherapi
agent
target
prostat
cancer
well
studi
variou
clinic
trial
van
den
eertwegh
et
al
studi
combin
two
activ
immunotherapi
approach
gvax
ipilimumab
treatment
metastat
castrationresist
prostat
cancer
wherea
gvax
design
amplifi
antitumor
respons
specif
prostat
cancer
cell
ipilimumab
contribut
tcell
activ
thu
author
present
possibl
augment
antitumor
tcell
activ
two
differ
way
immunotherapeut
agent
ipilimumab
help
address
signific
unmet
need
treatment
advanc
melanoma
ipilimumab
fulli
human
monoclon
antibodi
target
cytotox
tlymphocyt
therebi
augment
antitumor
immun
respons
ipilimumab
dose
mg
per
kilogram
combin
dacarbazin
compar
dacarbazin
plu
placebo
improv
overal
surviv
patient
previous
untreat
metastat
melanoma
ipilimumab
recent
approv
fda
treatment
metastat
melanoma
pivot
phase
iii
trial
treatment
sipuleucelt
proveng
dendreon
autolog
cellular
vaccin
consist
activ
antigenpres
cell
load
prostat
acid
phosphatas
pap
gave
median
overal
surviv
month
compar
month
placebotr
patient
result
rel
reduct
risk
death
cancer
immunotherapi
classifi
two
type
activ
passiv
activ
immunotherapi
stimul
immun
system
subdivid
specif
immunotherapi
includ
prophylact
therapeut
vaccin
nonspecif
immunotherapi
consist
compon
immun
system
cytokin
immun
adjuv
passiv
immunotherapi
use
boost
immun
system
passiv
transfer
monoclon
antibodi
increas
antitumor
immun
either
inhibit
immun
check
point
augment
stimulatori
signal
adopt
cell
therapi
involv
infus
tumorreact
cell
autolog
tumorinfiltr
lymphocyt
tcell
receptor
genemodifi
lymphocyt
chimer
antigen
receptor
recombin
receptor
provid
antigenbind
tcell
activ
function
prevent
treatment
cancer
vaccin
activ
specif
immunotherapi
attract
therapeut
option
mechan
action
eventu
enhanc
endogen
immun
respons
host
malign
antibodi
provid
protect
immun
system
microorgan
therapi
monoclon
antibodi
target
specif
tumor
proven
one
success
form
immun
therapi
cancer
antibodi
exert
role
bind
target
sever
effector
mechan
includ
steric
inhibit
neutral
complement
activ
activ
cellmedi
cytotox
monoclon
antibodi
therapi
rel
nontox
lesser
side
effect
chemotherapi
antibodi
bound
tumor
cell
nine
monoclon
antibodi
target
six
tumorassoci
protein
clinic
approv
treatment
cancer
exampl
rituximab
wide
use
monoclon
antibodi
use
combin
cyclophosphamid
doxorubicin
vincristin
prednison
nonhodgkin
lymphoma
shown
complet
remiss
patient
compar
chemotherapi
alon
monoclon
antibodi
ibritumomab
tiuxetan
tositumomab
use
target
tumor
directli
conjug
radioact
isotyp
toxic
chemic
case
gemcitumab
cytokin
cytokin
protein
secret
immun
cell
stimul
antigen
may
given
system
certain
cancer
potent
mediat
antivir
therapi
use
advanc
melanoma
renal
cell
carcinoma
cancer
resist
chemotherapi
alon
tumor
necrosi
factor
tnfa
anoth
cytokin
use
treatment
soft
tissu
carcinoma
limb
melanoma
purpos
cancer
vaccin
initi
activ
immun
respons
toward
tumor
sever
type
cancer
vaccin
develop
adenovir
dendrit
cell
tumor
cell
adopt
tcell
transfer
peptid
antigen
tumor
antigenpres
cell
may
use
potenti
vaccin
approach
enhanc
preexist
antitumor
immun
respons
perhap
case
induc
antitumor
immun
respons
exist
earlier
mani
potenti
sourc
tumor
antigen
includ
purifi
synthes
tumor
cell
surfac
molecul
may
peptid
protein
cell
lysat
deriv
fresh
cryopreserv
autolog
tumor
sampl
actual
mixtur
normal
malign
cell
cell
lysat
allogen
autolog
tumor
cell
line
varieti
method
tumor
antigen
present
includ
purifi
antigen
via
heat
shock
protein
virus
dna
antigenpres
cell
apc
dendrit
cell
idiotyp
monoclon
antibodi
mab
select
tumor
antigen
recognit
numer
molecul
might
use
adjuv
enhanc
immunogen
vaccin
cancer
vaccin
may
given
differ
rout
subcutan
intraderm
intramuscular
intraven
although
oral
rout
accept
rout
administr
among
patient
formul
oral
vaccin
face
number
challeng
still
mani
research
focus
aspect
formul
vaccin
use
novel
deliveri
system
microparticl
nanoparticl
chapter
touch
upon
research
carri
laboratori
oral
microparticul
vaccin
biolog
deliveri
long
assum
cancer
vaccin
could
elicit
strong
enough
immun
respons
could
overcom
tumorinduc
immun
suppress
poor
clinic
result
mani
promis
vaccin
realiz
immunogen
enough
addit
strong
vaccin
tumorinduc
immunosuppress
must
activ
reduc
may
achiev
combin
arsen
chemotherapi
agent
alreadi
use
phase
iii
trial
sipileucelt
proveng
dendreon
corpor
first
autolog
vaccin
consist
activ
dendrit
cell
compris
granulocytemacrophag
colonystimul
factor
gmcsf
prostat
acid
phosphatas
pap
approv
fda
treatment
advanc
prostat
cancer
vaccin
includ
larg
proport
antigenpres
cell
infus
back
patient
stimul
antitumor
tcell
respons
result
show
higher
median
overal
surviv
compar
placebotr
patient
result
rel
reduct
risk
death
fail
show
benefit
progressionfre
surviv
tumor
regress
rare
exampl
person
vaccin
chemotherapi
help
improv
efficaci
cancer
vaccin
exert
variou
effect
immun
system
howev
sever
pitfal
consid
chemotherapeut
regimen
differ
differ
cancer
stage
cancer
patient
characterist
ad
cancer
vaccin
program
introduc
anoth
layer
complex
inde
sever
studi
look
vaccin
chemotherapi
combin
highlight
fact
chemotherapi
must
care
dose
deliv
particular
time
relat
vaccin
optim
effect
although
substanti
research
combin
chemotherapi
vaccin
mous
model
inform
human
studi
rare
due
activ
role
immun
system
play
tumor
clearanc
like
benefit
cancer
vaccin
best
observ
patient
earli
untreat
diseas
gemcitabin
cyclophosphamid
dacarbazin
temozolomid
metabol
dacarbazin
vivo
particular
use
far
studi
report
safeti
risk
associ
chemotherapi
immunotherapi
recent
clinic
studi
combin
treatment
proven
chemotherapi
given
vaccin
better
treatment
strategi
chemotherapi
pretreat
simultan
administr
clinic
studi
publish
antonia
et
al
show
result
indic
patient
extens
stage
small
cell
lung
cancer
essenti
respons
secondlin
chemotherapi
treatment
vaccin
dendrit
cell
transduc
via
adenovir
vector
phase
ii
studi
person
peptid
vaccin
combin
anticanc
drug
gemcitabin
treat
advanc
pancreat
cancer
produc
respons
rate
cellular
humor
respons
melitac
peptid
cancer
vaccin
administ
cyclophosphamid
resect
stage
iib
iv
melanoma
phase
iii
studi
show
cyclophosphamid
provid
detect
improv
tcell
respons
clinic
outcom
addit
chemotherapi
studi
attempt
wherein
vaccin
respons
improv
inactiv
treg
cell
specif
target
tcell
receptor
monoclon
antibodi
ipilimumab
yervoy
bristolmy
squibb
preliminari
clinic
trial
suggest
administ
therapeut
vaccin
follow
ipilimumab
enhanc
immun
respons
tumor
reduct
prostat
ovarian
cancer
well
melanoma
similarli
transgen
murin
prostat
cancer
model
tumor
shrinkag
effect
observ
combin
therapi
whole
cell
gmcsfsecret
vaccin
gvax
lowdos
cyclophosphamid
one
two
day
immun
vaccin
alon
effect
associ
reduc
treg
popul
tumor
lymph
node
well
stimul
dendrit
cell
activ
apart
chemotherapi
vaccin
combin
novel
antibodi
target
certain
cancer
may
also
use
conjunct
certain
cancer
vaccin
anticanc
drug
exampl
antibodi
administ
cellbas
gmcsfsecret
vaccin
gvax
show
remark
increas
effector
tcell
respons
henc
possibl
boost
therapeut
advantag
vaccin
combin
chemotherapi
seen
case
mention
howev
research
area
mani
pose
problem
far
chemotherapeut
aspect
concern
dose
time
administr
differ
differ
chemotherapeut
regimen
variou
cancer
tradit
patient
last
stage
cancer
limit
therapeut
altern
test
experiment
therapi
case
patient
deterior
diseas
previou
chemotherapi
may
less
like
mount
strong
respons
vaccin
thu
may
ideal
candid
mani
question
remain
unansw
requir
investig
mani
experiment
strategi
yet
tri
determin
effect
combin
result
maximum
therapeut
benefit
minimum
side
effect
lab
use
particulatebas
deliveri
system
micromet
rang
nanomet
rang
deliv
via
discuss
rout
administr
particul
deliveri
system
gener
offer
mani
advantag
compar
tradit
method
drug
deliveri
includ
small
larg
molecul
accommod
multidrug
therapi
use
one
particl
stabl
deliveri
system
bioactiv
molecul
easi
manufactur
scaleup
elimin
coldchain
requir
neisseria
meningitidi
lead
caus
bacteri
mening
sepsi
young
children
young
adult
unit
state
associ
high
mortal
rate
childhood
vaccin
shown
induc
herd
immun
effect
reduc
nasopharyng
carriag
current
avail
polysaccharidebas
meningococc
vaccin
licens
use
adolesc
adult
expens
therefor
util
micro
nanotechnolog
explor
novel
meningococc
vaccin
formul
boost
innat
adapt
immun
offer
protect
import
anoth
import
aspect
note
micronanoparticl
could
facilit
oral
transderm
nasal
buccal
deliveri
vaccin
could
prove
incred
boon
deal
epidem
subsaharan
african
countri
need
train
medic
personnel
could
effect
avoid
needlefre
vaccin
gain
import
deal
countri
human
immunodefici
viru
hiv
signific
concern
improv
safeti
vaccin
capsular
polysaccharid
cp
major
virul
factor
meningococc
infect
form
basi
serogroup
design
protect
vaccin
cp
anchor
outer
membran
moieti
function
protect
bacteria
complementmedi
kill
also
inhibit
phagocytosi
profession
phagocyt
ubal
et
al
attempt
formul
microparticul
meningococc
vaccin
serv
sustainedreleas
system
administ
oralbucc
rout
vaccin
formul
consist
meningococc
cp
polym
serogroup
andor
adjuv
kdta
encapsul
albuminbas
biodegrad
matrix
microparticl
mimic
chemic
conjug
process
cp
protein
carrier
thu
enhanc
antigen
uptak
via
albumin
receptor
elicit
tcelldepend
immun
respons
abil
cpsload
microparticl
induc
cytokin
chemokin
releas
macrophag
investig
vitro
cell
cultur
model
human
macrophagelik
cell
dosedepend
releas
tnfa
figur
expos
meningococc
cpsload
microparticl
empti
microparticl
observ
cytokin
releas
reflect
recognit
immunostimulatori
activ
polysaccharid
antigen
microparticl
matrix
taken
togeth
data
suggest
cpsload
microparticl
recogn
macrophag
encapsul
bsa
matrix
hamper
immunostimulatori
activ
cp
autophagi
ancient
homeostasi
mechan
macromolecul
degrad
recent
recogn
play
role
host
defens
antigen
present
seen
cpsload
microparticl
empti
microparticl
strongli
induc
autophag
vacuol
dosedepend
manner
figur
innat
immun
recognit
vaccineload
microparticl
first
step
prerequisit
elicit
adapt
immun
respons
case
studi
briefli
describ
use
micronanoparticl
effect
altern
nonparenter
deliveri
bacteri
vaccin
pave
way
research
improv
field
vaccin
deliveri
influenza
virus
caus
highli
contagi
diseas
human
respiratori
tract
nose
lung
throat
symptom
influenza
infect
fever
sore
throat
headach
cough
fatigu
influenza
epidem
deadli
viru
kill
approxim
million
peopl
global
new
strain
influenza
viru
emerg
spread
quickli
throughout
world
caus
first
influenza
pandem
centuri
two
type
influenza
vaccin
flu
shot
nasalspray
flu
vaccin
flu
shot
contain
inactiv
influenza
viru
nasalspray
flu
vaccin
flumist
made
live
attenu
flu
virus
oral
administr
potenti
rout
vaccin
need
train
medic
personnel
administr
thu
lead
increas
coverag
vaccin
seen
case
oral
polio
vaccin
develop
novel
influenza
oral
vaccin
signific
impact
improv
public
health
one
case
studi
microparticul
vaccin
develop
use
inactiv
influenza
viru
antigen
incorpor
polym
matrix
eudragit
vivo
test
balbc
mice
immun
two
dose
within
threeweek
interv
serum
sampl
analyz
prove
microparticul
vaccin
enhanc
antigenspecif
antibodi
figur
also
mice
challeng
heterolog
influenza
virus
result
show
signific
induct
level
protect
via
technolog
anoth
trend
develop
influenza
vaccin
minim
number
dose
one
innov
approach
broaden
protect
efficaci
use
extracellular
domain
matrix
protein
antigen
common
among
influenza
virus
group
replac
hyperimmunogen
region
salmonella
enterica
serovar
typhimurium
flagellin
flic
four
repeat
fuse
membran
anchor
influenza
viru
hemagglutinin
establish
membraneanchor
fusion
protein
fusion
protein
integr
influenza
viruslik
particl
vivo
studi
show
strong
antigenspecif
antibodi
case
intramuscular
intranas
administr
novel
therapeut
approach
develop
influenza
vaccin
via
transderm
rout
investig
use
microneedl
technolog
influenza
viruslik
particl
deliv
microchannel
skin
show
induct
protect
influenza
infect
prove
longtem
protect
efficaci
studi
influenza
virusspecif
total
igg
hemagglutin
inhibit
titer
maintain
high
level
one
year
vaccin
addit
level
lung
igg
iga
antibodi
respons
higher
compar
intramuscular
administr
overal
mani
innov
technolog
appli
develop
enhanc
influenza
vaccin
divers
antigen
inactiv
virus
live
attenu
virus
protein
viruslik
particl
studi
along
variou
rout
administr
transderm
intranas
intramuscular
oral
novel
approach
would
promis
influenza
vaccin
better
protect
influenza
virus
could
substanti
reduc
burden
public
health
futur
human
papillomaviru
hpv
sexual
transmit
viru
caus
genit
wart
lead
cancer
cervix
vulva
vagina
peni
oropharynx
throat
approxim
women
diagnos
cervic
cancer
number
could
rise
new
case
annual
absenc
intervent
least
distinct
type
hpv
includ
hpv
type
develop
infect
human
therefor
hpv
vaccin
strongli
recommend
femal
male
especi
girl
age
current
two
prophylact
hpv
vaccin
commerci
worldwid
bival
vaccin
cervarix
glaxosmithklin
gardasil
merck
howev
vaccin
inject
expens
approxim
cours
three
dose
consequ
afford
peopl
develop
countri
numer
novel
approach
hpv
vaccin
regard
differ
rout
administr
intranas
oral
transderm
type
antigen
viruslik
particl
dna
protein
one
studi
proteinbas
hpv
prophylact
cancer
vaccin
test
mice
administ
intranas
combin
antigen
tolllik
receptor
flab
result
show
combin
elicit
strong
antigenspecif
cytotox
tlymphocyt
activ
antigenspecif
interferon
product
spleenocyt
cervic
lymph
node
cell
novel
approach
could
prove
effect
prophylact
hpv
vaccin
futur
dnabas
vaccin
anoth
excel
altern
target
hpv
infect
cervic
cancer
exampl
recombin
vector
use
antigen
pass
microchannel
skin
use
microneedl
array
studi
balbc
mice
immun
one
prime
follow
two
booster
everi
two
week
serum
lymphocyt
collect
detect
function
humor
cellular
immun
result
prove
dna
vaccin
promis
platform
transderm
deliveri
via
microneedl
induc
specif
antibodi
vitro
vivo
studi
recent
nineval
vaccin
hpv
hpv
propos
better
protect
hpv
infect
cervic
cancer
nineval
vaccin
induc
immun
strong
gardasil
cervarix
world
incid
rate
could
dramat
reduc
summari
mani
novel
approach
altern
hpv
vaccin
propos
improv
efficaci
reduc
cost
variou
rout
administr
test
along
differ
type
antigen
includ
protein
peptid
dna
viruslik
particl
varieti
adjuv
incorpor
antigen
stimul
humor
cellular
immun
respons
hpv
infect
cervic
cancer
prostat
gland
part
male
reproduct
system
locat
bladder
front
rectum
nation
cancer
institut
nci
report
approxim
case
prostat
cancer
alon
second
lead
caus
cancerrel
death
america
europ
primari
goal
cancer
immunotherapi
destruct
tumor
immun
system
sever
strategi
elicit
effect
antitumor
respons
includ
design
vaccin
target
specif
tumor
epitop
modul
activ
regulatori
cell
dampen
underli
immun
respons
mani
prostatespecif
antigen
known
immunogen
one
antigen
prostatespecif
antigen
psa
also
serv
marker
diseas
progress
nanoparticl
microparticl
forefront
drug
deliveri
recent
year
investig
focus
use
platform
improv
sever
aspect
vaccin
deliveri
particul
vaccin
offer
distinct
advantag
antigen
solut
protect
antigen
vivo
environ
improv
uptak
antigen
reduc
number
dose
primari
immun
use
target
specif
cell
popul
enhanc
efficaci
sever
studi
laboratori
prove
efficaci
oral
microparticul
system
elicit
immun
respons
tumor
mechan
immun
system
activ
oral
rout
explain
earlier
section
chapter
laboratori
also
explor
sever
target
ligand
target
cell
order
enhanc
sitespecif
uptak
microparticl
microparticl
formul
use
spraydri
technolog
enter
polym
fall
gener
regard
safe
gra
categori
classifi
fda
preliminari
studi
laboratori
evalu
efficaci
microparticul
whole
cell
lysat
vaccin
prostat
cancer
cell
prophylact
cancer
vaccin
therapi
observ
tumor
growth
significantli
retard
vaccin
mice
compar
control
group
recent
chirivainternati
et
al
isol
test
target
prostat
cancerspecif
immunotherapi
lab
current
explor
efficaci
therapeut
oral
microparticul
vaccin
prostat
cancer
preliminari
studi
indic
along
whole
cell
lysat
microparticul
vaccin
system
could
effici
induc
antitumor
immun
respons
lead
signific
reduct
tumor
growth
vivo
use
transderm
drug
deliveri
deliveri
oligonucleotid
protein
peptid
inactiv
virus
grow
steadili
microneedl
microns
needl
length
mm
microneedl
pierc
upper
layer
skin
local
system
deliveri
small
molecul
drug
biolog
deliveri
vaccin
skin
establish
promis
target
elicit
immun
respons
laboratori
studi
efficaci
whole
cell
lysat
vaccin
microparticl
murin
prostat
cancer
cell
tramp
mice
vaccin
perform
transderm
rout
mice
challeng
live
murin
prostat
cancer
cell
follow
immun
tumor
growth
monitor
week
result
studi
prove
mice
vaccin
transderm
rout
elicit
delay
tumor
growth
signific
compar
control
group
figur
mechanist
studi
reveal
increas
cell
b
cell
vaccin
mice
compar
control
thu
observ
innat
adapt
immun
respons
activ
follow
transderm
vaccin
delay
tumor
growth
vaccin
mice
breast
cancer
one
common
type
cancer
femal
world
accord
center
diseas
control
prevent
cdc
case
report
women
die
breast
cancer
past
decad
exponenti
growth
research
conduct
immunotherapi
immunotherapi
work
induc
enhanc
bodi
immun
system
identifi
reject
tumor
sever
breast
cancer
antigen
human
epiderm
growth
factor
receptor
mucin
human
telomeras
revers
transcriptas
htert
tumor
protein
cancer
embryon
antigen
cea
use
prepar
vaccin
tumorassoci
antigen
taa
repres
whole
cell
extractsdendrit
cell
dna
motif
whole
cell
vaccin
formul
microparticl
use
enter
coat
polym
microparticl
formul
optim
use
differ
combin
concentr
polym
microparticl
administ
oral
transderm
vitro
vivo
studi
carri
evalu
humor
cellular
respons
vaccin
load
microparticl
vitro
experi
show
spraydri
microparticl
provid
protect
gastric
condit
control
releas
six
hour
vaccineload
particl
nontox
normal
cell
major
particl
size
rang
mm
vivo
studi
prove
oral
transderm
group
abl
prevent
delay
tumor
growth
compar
control
group
receiv
blank
microparticl
flow
cytometri
result
immun
organ
reveal
anim
receiv
vaccin
show
higher
cell
level
control
group
higher
express
marker
show
vaccin
particl
abl
induc
better
immun
respons
fight
cancer
cell
efficaci
vaccin
microparticl
could
seen
tumor
volum
data
figur
therapeut
applic
vaccin
microparticl
current
evalu
therapeut
efficaci
vaccin
microparticl
reportedli
enhanc
given
combin
cytotox
drug
adjuv
melanoma
danger
form
skin
cancer
character
malign
prolifer
melanocyt
one
lead
caus
death
rate
occurr
world
progress
increas
peopl
expos
larger
amount
damag
ultraviolet
ray
due
vanish
ozon
layer
earli
stage
melanoma
local
treatabl
larg
extent
time
tumor
metastas
viscer
organ
make
difficult
treat
recent
studi
carri
american
cancer
societi
melanoma
locat
near
start
fiveyear
surviv
rate
fiveyear
surviv
rate
melanoma
spread
nearbi
lymph
node
part
bodi
respect
melanoma
account
skin
cancer
case
caus
skin
cancer
death
standard
approv
treatment
melanoma
includ
surgeri
target
therapi
radiat
chemotherapi
treatment
biolog
current
treatment
approv
fda
includ
ifna
dacarbazin
requir
supplement
treatment
option
surgeri
radiat
extens
studi
conduct
mayo
clinic
determin
effici
chemotherapeut
agent
melanoma
cancer
patient
achiev
complet
remiss
patient
undergon
surgeri
complet
remov
tumor
high
risk
relaps
system
given
high
dose
pegyl
approv
adjuv
treatment
prospect
random
control
trial
agent
shown
increas
overal
surviv
compar
observ
novel
monoclon
antibodi
ipilimumab
vemurafenib
approv
fda
demonstr
improv
overal
surviv
intern
random
trial
patient
advanc
melanoma
singl
agent
rare
cur
howev
clinic
trial
incorpor
agent
test
combin
attempt
prevent
develop
drug
resist
vemurafenib
select
braf
kinas
inhibitor
indic
limit
patient
demonstr
braf
mutat
fdaapprov
test
approv
fda
basi
durabl
complet
respons
cr
rate
minor
patient
previous
treat
metastat
melanoma
eight
phase
ii
studi
nation
cancer
institut
mention
interferon
type
biolog
therapi
use
treat
melanoma
interferon
slow
tumor
progress
affect
divis
cancer
cell
improv
growth
activ
mani
immun
cell
especi
lymphocyt
lymphocyt
attack
kill
cancer
cell
tumor
necrosi
factor
tnf
therapi
anoth
type
biolog
therapi
use
conjunct
treatment
melanoma
tnf
cytokin
releas
white
blood
cell
respons
antigen
infect
success
prophylact
vaccin
infecti
diseas
increas
interest
research
explor
feasibl
use
vaccin
cancer
john
wayn
cancer
institut
santa
clara
ca
develop
vaccin
regimen
form
live
whole
cell
melanoma
vaccin
call
cancervax
vaccin
includ
mixtur
irradi
melanoma
associ
antigen
maa
deriv
allogen
tumor
cell
line
treat
melanoma
result
vaccin
studi
show
median
surviv
rate
melanoma
patient
significantli
higher
compar
patient
receiv
form
treatment
turn
led
interest
develop
vaccin
would
trigger
immun
system
stimul
cytotox
cell
inhibit
tumor
growth
recent
year
research
focus
develop
novel
vaccin
whole
cell
vaccin
dendrit
cell
vaccin
peptid
vaccin
dna
vaccin
viral
vaccin
gangliosid
vaccin
either
prevent
treatment
melanoma
melanoma
vaccin
test
shown
poor
clinic
respons
thu
effect
vaccin
develop
date
vaccin
test
howev
given
parenter
rout
oral
vaccin
current
investig
efficaci
stimul
mucos
well
system
immun
mucos
rout
entri
initi
primari
immun
respons
well
establish
pathogen
invas
microb
enter
host
system
via
region
small
intestin
bernadett
et
al
describ
studi
wherein
formul
novel
prophylact
oral
microparticul
vaccin
compos
whole
cell
lysat
melanoma
use
spraydri
techniqu
surfac
morpholog
microparticl
evalu
scan
electron
microscopi
sem
show
particl
spheric
surfac
size
distribut
around
mm
figur
use
mcell
target
ligand
call
aleuria
aurantia
lectin
improv
uptak
peyer
patch
small
intestin
result
suggest
melanoma
antigen
microparticl
abl
significantli
increas
antibodi
titer
mice
group
contain
lectin
ligand
comparison
group
involv
studi
serum
igg
respons
oral
immun
mice
aal
ligand
vaccin
compar
oral
group
without
novel
therapeut
approach
aal
show
signific
increas
serum
igg
titer
result
tumor
challeng
studi
show
group
vaccin
aalassoci
microparticl
show
highest
level
protect
tumor
develop
thu
futur
design
oral
particul
vaccin
aal
may
incorpor
formul
target
ligand
major
challeng
design
success
vaccin
deliveri
antigen
part
immun
system
maximum
stimul
prolifer
profession
immunopot
cell
achiev
previou
studi
model
antigen
shown
microparticl
capabl
exhibit
potent
serum
antibodi
respons
entrap
antigen
follow
oral
administr
figur
repres
cytotox
evalu
melanomaantigen
microparticl
vitro
cell
cultur
model
data
show
cell
viabil
measur
novel
therapeut
approach
averag
n
se
hour
incub
microparticl
microparticl
formul
ad
dose
mgml
ml
complet
cell
cultur
media
cell
alon
media
use
neg
control
atropin
sulfat
cytotox
agent
posit
control
result
cell
death
studi
current
aim
combin
chemotherapi
novel
immunotherapi
includ
vaccin
cytokin
antibodi
hundr
combin
therapi
current
undergo
clinic
trial
vaccin
therapi
still
remain
experiment
therapi
patient
metastat
melanoma
vaccin
deliveri
formul
demonstr
investig
describ
open
new
avenu
vaccin
administr
patientconveni
rout
cancer
therapi
research
need
although
futur
therapi
advanc
melanoma
probabl
multimod
approach
includ
vaccin
adjuv
neg
costimulatori
blockad
among
gynecolog
cancer
ovarian
cancer
lethal
fifth
lead
caus
cancerrel
death
women
global
specif
unit
state
accord
data
cdc
year
around
women
us
diagnos
ovarian
cancer
women
sadli
die
year
due
ovarian
cancer
major
reason
high
mortal
women
ovarian
cancer
diagnos
advanc
diseas
mani
vaccin
made
clinic
trial
progress
beyond
phase
iii
studi
although
antigenspecif
respons
obtain
use
variou
approach
immun
lack
consist
benefit
discuss
oral
vaccin
microparticl
contain
ovarian
cancer
antigen
prevent
retard
ovarian
cancer
growth
murin
ovarian
cancer
cell
line
use
sourc
antigen
correl
close
human
ovarian
cancer
cell
line
signal
pathway
result
develop
tumor
mice
model
similar
human
ovarian
cancer
whole
cell
lysat
promis
approach
provid
pool
tumorassoci
antigen
taa
includ
cell
also
overcom
drawback
associ
use
singl
antigen
epitop
vaccin
like
studi
protect
antigen
gastric
condit
enter
polym
methacryl
copolym
fs
hydroxyl
methylcellulos
succin
hpmca
use
make
microparticl
along
aal
mcell
target
properti
use
spraydryer
method
figur
addit
inclus
immunostimulatori
molecul
evalu
order
enhanc
overal
potenc
formul
vaccin
character
vaccin
particl
done
immunogen
microparticul
vaccin
evalu
use
femal
mice
model
three
differ
formul
placebo
vaccin
vaccin
interleukin
evalu
efficaci
tumor
challeng
studi
carri
one
week
last
vaccin
administ
mice
challeng
live
cell
subcutan
tumor
volum
check
reduct
tumor
volum
indic
success
vaccin
formul
morpholog
character
particl
show
particl
crumbl
collaps
irregular
shape
within
micromet
size
rang
net
posit
charg
immun
studi
show
group
mice
placebo
particl
tumor
growth
rapid
vaccin
group
sixfold
tumor
suppress
compar
placebo
howev
much
differ
vaccin
group
group
interleukin
could
possibl
due
low
concentr
interleukin
access
humor
immun
respons
bcell
mediat
serum
sampl
collect
dose
analyz
enzymelink
immunosorb
assay
elisa
igg
subtyp
igg
igg
result
elisa
show
increas
igg
titer
vaccin
mice
oppos
nonvaccin
mice
thu
subtyp
igg
indic
mix
type
respons
gener
vaccineonli
group
type
respons
trigger
among
interleukin
group
differ
could
attribut
effect
interleukin
peyer
patch
previous
report
strategi
increas
immun
respons
oral
vaccin
similar
studi
carri
marinaro
et
al
given
oral
mice
immun
oral
tetanu
toxoid
cholera
toxin
studi
show
oral
result
respons
oral
vaccin
respons
occur
given
via
intraperiton
rout
check
tcell
popul
lymphat
organ
spleen
lymph
node
collect
level
elev
vaccin
mice
compar
placebo
group
tcell
popul
found
elev
spleen
cell
vaccin
interleukin
group
compar
spleen
cell
vaccinealon
group
bcell
popul
determin
spleen
lymph
node
bone
marrow
bcell
popul
spleen
cell
elev
level
vaccin
interleukin
group
compar
placebo
vaccin
alon
b
cell
bone
marrow
found
elev
vaccin
interleukin
group
compar
placebo
vaccinealon
group
summari
bcell
popul
found
elev
bone
marrow
spleen
cell
vaccin
interleukin
group
compar
vaccinealon
group
higher
lymph
node
vaccinealon
group
well
vaccin
interleukin
group
compar
placebo
found
cell
expand
mice
treat
vaccin
without
interleukin
compar
nonvaccin
mice
figur
howev
comparison
made
vaccinealong
group
vaccin
interleukin
group
bcell
popul
bone
marrow
spleen
along
cell
spleen
found
elev
vaccin
interleukin
group
novel
therapeut
approach
thu
overal
stimul
humor
cellular
respons
upon
administr
vaccin
indic
success
vaccin
result
also
correl
tumor
volum
reduct
mice
thu
studi
demonstr
efficaci
microparticul
vaccin
contain
whole
cell
lysat
oral
vaccin
deliveri
could
effect
attract
mode
immun
eas
administr
low
cost
manufactur
importantli
patient
complianc
today
still
increas
number
new
vaccin
develop
prevent
differ
evolv
diseas
includ
bird
flu
acquir
immunodefici
syndrom
aid
sever
acut
respiratori
syndrom
sar
other
nevertheless
main
vaccin
rout
still
subcutan
intramuscular
rout
administr
method
render
vaccin
unafford
mani
area
thirdworld
countri
use
spray
dryer
formul
develop
process
perform
demonstr
feasibl
scaleup
manufactur
one
hurdl
oral
protein
vaccin
deliveri
harsh
acid
environ
stomach
overcom
obstacl
enter
coat
polym
variou
combin
matric
use
protect
protein
protect
suffici
ensur
success
deliveri
encapsul
biolog
vaccin
anoth
featur
formul
develop
sustainedor
controlledreleas
properti
achiev
employ
differ
combin
polym
featur
tailor
achiev
desir
releas
profil
adjust
composit
polym
use
light
fact
protein
sensit
subtl
chang
microenviron
therefor
stabil
encapsul
protein
must
evalu
achiev
physicochem
characterist
formul
develop
analyz
use
bioactiv
assay
fourier
transform
infrar
ftir
spectroscopi
differenti
scan
calorimetri
dsc
particl
size
analyz
zetas
addit
ftir
dsc
studi
perform
microencapsul
show
major
chang
nativ
structur
result
suggest
formul
develop
use
effect
vehicl
deliveri
protein
vaccin
